ARROWHEAD PHARMACEUTICALS, INC.
ARWR · NASDAQ
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
Market Data
Price
$55.05
+0.04 (+0.07%)
Market Cap$7.71B
P/E Ratio38.11
EPS$—
52W High$76.76
52W Low$9.57
Beta1.30
Data from Finnhub · Updated Mar 15, 2026